Health And Pharma
WEBHealth & Pharma. Health and Pharma is a new-generation international news and communication platform. Our goal is to collaborate with health science and pharma professionals to report directly from the news sources and strive to be recognized as a trusted news platform.
FDA Approves IMDELLTRA for Lung Cancer After a 40% Response …
WEBMay 17, 2024 · A New Era in SCLC Treatment. Small cell lung cancer, particularly the extensive-stage disease, has long been a formidable challenge in oncology, with fewer than 3% of patients surviving beyond five years post-diagnosis.IMDELLTRA's mechanism of action involves the activation of the patient's own T-cells to attack cancer cells expressing DLL3, offering a new hope for durable treatment responses.
Bayer's New Lung Cancer Drug Receives Critical FDA Breakthrough …
WEB1 March 2024. Bayer announced that its investigational drug BAY 2927088 has been awarded the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). This promising development brings new hope to patients battling non-small cell lung cancer (NSCLC) with specific HER2 activating mutations, offering a potential new avenue ...
The LUMINOSITY Trial: Exploring c-Met and SEZ6 Targets in the …
WEB2 days ago · Antibody-drug conjugates (ADCs) represent a significant breakthrough in oncology, offering targeted treatments, especially for lung cancer. In this exclusive interview, we speak with Professor Nicolas Girard, Head of the Curie-Montsouris Thorax Institute at Institut Curie and Professor of Respiratory Medicine at Versailles Saint Quentin University, to explore the latest advancements in ADC ...
APS2 Blood Test for Alzheimer's Could Revolutionize Early …
WEBJul 29, 2024 · New research highlights the effectiveness of the APS2 blood tests in diagnosing Alzheimer's disease with up to 90% accuracy, potentially replacing costly and invasive conventional methods. Presented at AAIC 2024 and published in JAMA, the study shows APS2's superiority in both primary and specialized care, …
Anixa's CAR-T Therapy for Ovarian Cancer Earns FDA IND Approval
WEBJul 25, 2024 · The FDA approved a second dose of CAR-T therapy for ovarian cancer developed by Anixa Biosciences following promising initial results. This therapy, which has shown potential in reducing tumor size and enhancing immune response, offers new hope for patients with advanced ovarian cancer who have exhausted other treatment options.
Merck's Keytruda Achieves Key Milestone in Early-Stage Lung …
WEBOct 11, 2023 · The KEYNOTE-671 trial results are significant in the ongoing battle against lung cancer. At a pre-specified interim analysis, the study showed that patients receiving Keytruda combined with chemotherapy before surgery, followed by Keytruda post-surgery, experienced a notable improvement in OS.
A New Era in Oncology: Programmable mRNA Therapies in the …
WEBApr 4, 2024 · Strand Therapeutics promises a new class of cancer treatment with its programmable mRNA therapies designed to precisely target cancer cells. With FDA clearance for a Phase 1 trial of their lead therapy, STX-001, they aim to improve solid tumor treatment outcomes and advance personalized medicine. Strand Therapeutics, an enterprise born from the ...
A New Era in Liver Disease: FDA Approves First Medication …
WEB15 March 2024. The FDA has approved Rezdiffra, the first medication for the treatment of nonalcoholic steatohepatitis (NASH), offering hope to millions with liver scarring. Developed by Madrigal Pharmaceuticals, it improves liver fibrosis and resolves NASH in patients with moderate to advanced fibrosis, signaling a significant advancement in ...
BioNTech's Endometrial Cancer Drug Receives FDA Breakthrough …
WEBDec 22, 2023 · Evaluating this historical development, Prof. Özlem Türeci, Chief Medical Officer and Co-Founder at BioNTech, emphasizes her optimism, stating, “The Breakthrough Therapy designation for BNT323/DB-1303 shows the potential of our ADC candidate to address current treatment challenges for patients with advanced HER2-expressing endometrial cancer who progressed under several lines of systemic ...